Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]

Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.

Study results suggest that selected interventions should be based on phenotypic differences and treatment goals.

Non-Hispanic Black and Hispanic or Latino individuals on ocrelizumab did not demonstrate significantly greater risk on 24-week confirmed disability progression relative to non-Hispanic Whites.

Majority of patients with relapsing multiple sclerosis demonstrated achieving and maintaining no evidence disease activity after being treated with ublituximab.

The program committee vice-chair of ACTRIMS discussed the continued efforts to understand inflammation and neurodegeneration of multiple sclerosis. [WATCH TIME: 3 minutes]

The program committee vice-chair of ACTRIMS provided perspective on the upcoming forum, including the notable sessions, themes, and presentations the clinical community should be aware of. [WATCH TIME: 7 minutes]

Daniel Ontaneda, MD, program committee vice-chair of ACTRIMS, provided insight on the notable sessions and themes clinicians should pay attention to at this year’s forum, which takes place February 23-25, in San Diego, California.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]

Speaking on his own presentation on economic burden in MS, Bruce Bebo, PhD, further shared his thoughts on areas of unmet need and the potential relationship of Epstein-Barr virus and MS.

A systematic literature review of randomized controlled trials in neuromyelitis optica spectrum disorder was performed, with 7 studies identified and 2 used in analyses.

Investigators noted the long-term cost-effectiveness and safety of this approach, as it does not require the regular use of disease-modifying therapies.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]

Bruce Bebo, PhD, outlined findings from a recent analysis presented at ACTRIMS Forum 2022, with investigators concluding costs associated with the disease have previously been underestimated.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

Data provide an update to the post-approval safety profile of cladribine tablets in patients with relapsing MS in reference to COVID-19 infections.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.

Previously reported data show patients with multiple sclerosis treated with anti-CD20s have reduced response to COVID-19 vaccines, but there has been limited research on MS outcomes among vaccinated patients.

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed her presentation at ACTRIMS Forum 2022 involving imaging biomarkers of RIS/MS prodrome. [WATCH TIME: 4 minutes]

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis Treatment and Research discussed the results of a new study on age and sex as determinants of autoimmune encephalitis. [WATCH TIME: 3 minutes]

Investigators noted the need for more transformational treatments to improve disability for patients with both primary and secondary progressive multiple sclerosis.

Data suggest that there is a greater cognitive benefit for patients with higher levels of baseline neurological disability treated with the training and transcranial direct current stimulation.

The professor of neurology at the NYU Grossman School of Medicine discussed her presentation at ACTRIMS Forum 2022, which showed better cognitive outcomes in MS following treatment with tDCS. [WATCH TIME: 3 minutes]

The assistant professor of neurology at the University of Pennsylvania provided insight on a new way to accurately predict chronic active lesion evolution from newly developing MS lesions using 7T MRI.

The study found that all COVID-19 cases were mild to moderate in severity, and all enrolled patients recovered and remained in the study.

Investigators utilized a novel method to accurately capture spinal cord area at C1 vertebral level from legacy brain MRI scans.

The executive vice president of the National MS Society spoke on recently published data suggesting the relationship between EBV and MS, also sharing his opinion on the potential of vaccines. [WATCH TIME: 2 minutes]

Most trials that reported on MS-related fatigue measured its change from baseline and whether that change was statistically significant.

The assistant professor of neurology at the University of Pennsylvania discussed his abstract at ACTRIMS Forum using 7T MRI features of newly developed MS lesions to predict chronic active lesions. [WATCH TIME: 4 minutes]

Regardless of prophylactic or therapeutic paradigms, treatment with evobrutinib resulted in significantly reduced disease severity and improvement of immunopathological parameters of MS disease.